Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board
GOTHENBURG, Sweden, April 8, 2022 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), proposes that Jan […]
English
Isofol Medical AB (publ) publishes year-end report, January – December 2021
GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report
Invitation to presentation of Isofol’s year-end report 2021 on February 24, 2022
GOTHENBURG, Sweden, February 14, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s year-end report
Isofol recognizes World Cancer Day on February 4
Today, February 4, is World Cancer Day (https://www.worldcancerday.org/), and we at Isofol are sending our thoughts to those affected by advanced
Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer
GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the appointment of Jenny Sundqvist
Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET
GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on December 3 that the ongoing
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)
GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol Medical AB (publ) publishes interim report for January – September 2021
GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report